Ferrari Shares Decline After Unveiling First Electric Vehicle Amid Market Skepticism
Indian Rupee Rebounds Past 96 on Strong RBI Intervention
Taiwan Chip Stocks Climb After Nvidias 150 Billion Spending Commitment
US Seeks to Expand American AI Integration Across Asia After TrumpXi Engagement
Retail Sales Post Solid Gain Yet Early Signals of Consumer Pullback Emerge
Pope Leos Encyclical on AI Draws Ethical Lines as Anthropic Attends Signing
LOAR Q1 2026 Earnings EPS Surges 1087 Above Estimates Stock Edges Lower
FOXF Q1 2026 Earnings EPS Beats Estimates by 1153 Amid Cost Discipline
NKE Q1 2026 Earnings Strong EPS Beat Amidst Uncertain Revenue Landscape
Ascent Industries Co ACNT Q1 2025 Earnings Losses Widen as EPS Misses Estimates Sharply
SCCE Q4 2025 Earnings EPS Surges Past Estimates on Solid Performance
Newton Golf Q1 2026 Earnings Deeper Loss Than Expected as PreRevenue Company Navigates Development Phase
Macys Inc M Holds Steady Near Support A Test of Resilience
Ellington Credit Company EARN Bounces Modestly Support Holds Near 457
Twilio TWLO Slips 43 as Selling Pressure Intensifies Support at 172 in Focus
Bank of the James Financial Group BOTJ Holds Steady with Modest Gains Amid Support Levels
Proto Labs PRLB Holds Steady Near Support as Modest Gains Signal Consolidation
Market Breadth Weakness May Keep Nifty RangeBound Sudeep Shah Shares Views on Amber Tata Comm and Other Stocks
LYEL Q1 2026 Earnings Significant EPS Beat Driven by Operational Efficiency and Pipeline Progress
The Hartford Insurance Group HIG Edges Lower Consolidation Within Established Technical Range
SPMC Q1 2026 Earnings EPS Misses Estimates Despite Stock Rally
SUPV Q1 2026 Earnings Massive EPS Beat as Company Swings to Profitability
Hub Group Q3 2025 Earnings Slight EPS Miss Amid Mixed Freight Conditions
Nephros Q1 2026 Earnings EPS Misses Estimates by a Hair Shares Edge Higher
Aptiv PLC Q1 2026 Earnings Strong EPS Beat Driven by Operational Efficiency
Butterfly Network BFLY Q1 2026 Earnings NarrowerthanExpected Loss Fuels Investor Caution
Marker Therapeutics Q1 2026 Earnings NarrowerthanExpected Loss as Clinical Pipeline Progresses